期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 92, 期 3, 页码 251-263出版社
SPRINGER
DOI: 10.1007/s10549-005-3375-z
关键词
estrogen receptor; growth factor receptor tyrosine kinase; HER-2/neu; signal transduction; tamoxifen; trastuzumab (Herceptin)
类别
Extensive interactions between estrogen receptor alpha (ER alpha) and HER2 signaling pathways have been described. Using BT-474 human breast cancer cells, we have previously shown that the combination of tamoxifen (TAM) and Herceptin results in strong synergistic growth inhibition, enhancement of G(0)-G(1) cell cycle accumulation, inhibition of HER2 activity and a cytostatic effect without cell death. To further examine the underlying mechanism of synergy, we investigated the effect of this drug combination on ER alpha function and growth factor downstream signaling. TAM caused a small increase in ER alpha levels while Herceptin had no effect, and both drugs caused an increase in the level of Ser118-phosphorylated ER alpha. However, both TAM and Herceptin individually inhibited ER alpha transcriptional activity, although the combination did not have a greater effect than either single agent. Herceptin inhibited MAPK and Akt activity, while TAM had no effect on these either as a single agent or when added to Herceptin. Using a BALB/c athymic BT-474 in vivo xenograft model, the drug combination (Herceptin 0.3 mg/kg i.p. twice weekly, TAM 1.0 mg/mouse i.p. three times per week) showed a greater inhibition of tumor growth compared to either single agent. Tumor extracts and fixed sections were examined at the end of the treatment period for treatment-specific alterations: we noted a paradoxical proliferation-inducing effect of TAM that was reversed by the addition of Herceptin. Our results indicate that combined targeting of both peptide growth factor receptors and ER alpha represents a promising breast cancer treatment strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据